Figure. 2.

Transplanted ESHF derived CDCs outperformed CHD derived CDCs in preserving cardiac function after myocardial infarction in immunodeficient rats. Echocardiogram analysis was performed before and after surgery at day 7 days and day 28. (A) Left ventricle blood pool fractional area change in diastole (FAC, ejection fraction) was significantly improved in infarcted hearts transplanted with ESHF derived CDCs compared to transplanted CHD derived CDCs (*P<0.05), control (**=P<0.01), and Cfb (***P<0.001) at 7 and 28 days (B) As another age-matched cohort, CDCs derived from ESHF outperformed CDCs derived from donor hearts (DNR) in the preserving left ventricle ejection fraction in the immunodeficient myocardial infarct model at 28 days (*P<0.05). (C, D) Transplanted ESHF derived CDCs and CHD derived CDCs significantly improved hemodynamics when compared to controls as measured by −dP/dt (*P<0.05) and +dP/dt (*P< 0.05). (E–I) Infarct size determined by Masson’s trichrome staining was reduced with transplanted ESHF derived CDCs when compared with control (***=P<0.001), cardiac fibroblast (**=P<0.01), and CHD derived CDCs (*P<0.05). Data are analyzed by 2-Way ANOVA followed by Benferroni’s analysis or one–way ANOVA (non-parametric, Kruskal-Wallis test) followed by Dunns analysis. Data are presented as mean ± SEM.